Sign in to fuzzto save your conversations, follow your research and come back anytime.
Bharat Parenterals
BPLPHARMA
NSE
BSE
NSEBSESectorHealthcare
1,520.80
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Parent company operations rebound strongly in Q1 FY27, but consolidated results remain under pressure from subsidiary losses.
EBITDA for Bharat Parenterals Limited grew from ₹0.03 Cr in Q4 FY26 to ₹6.8 Cr in Q1 FY27 — signaling a strong operational recovery
Consolidated PAT widened to -₹3.6 Cr in Q1 FY27 from -₹0.8 Cr in Q4 FY26 — dragging down group profitability
PAT for the parent company rose from ₹1.3 Cr in Q4 FY26 to ₹3.7 Cr in Q1 FY27 — restoring bottom-line profitability
Innoxel Lifesciences PAT loss deepened from -₹7.6 Cr in Q4 FY26 to -₹10.4 Cr in Q1 FY27 — signaling ongoing operational strain
EBITDA margin expanded from 0.1% in Q4 FY26 to 12.3% in Q1 FY27 — reflecting improved pricing power
Consolidated EBITDA slipped from ₹1.8 Cr in Q3 FY26 to -₹0.09 Cr in Q1 FY27 — highlighting margin pressure across the group
Capacity utilization held steady at 21% for Beta-Lactam and 48.5% for General Block from Q4 FY26 to Q1 FY27 — supporting consistent output
Consolidated revenue from operations eased from ₹99.6 Cr in Q4 FY26 to ₹93.7 Cr in Q1 FY27 — indicating a slight sales slowdown
Order book remained stable at ₹171 Cr from Q4 FY26 to Q1 FY27 — providing clear visibility for upcoming production
Other operating revenue dropped from ₹3.6 Cr in Q4 FY26 to ₹1.1 Cr in Q1 FY27 — reducing supplementary income streams